Delcath 10-Q Details Q3 Profit: $35.1M Revenue, $7.0M Net Income, $104M Cash
DCTH has more than doubled off its 52-week low of $8.12.
Summary
Delcath's Q3 10-Q backs up this morning's headline beat with an 89% gross margin, $7.1M of operating income and $104.3M in cash and investments, while R&D and SG&A stepped up on the Phase 2 trial expansion.
Key Events · Earnings and Guidance · DCTH
-
Q3 Revenue Jumps 71% to $35.1M
Product revenue rose to $35.1M from $20.6M a year earlier, led by HEPZATO KIT at $32.7M versus $19.3M; CHEMOSAT contributed $2.4M versus $1.3M.
-
Operating Income Turns Positive at $7.1M
Gross profit of $31.2M (about 89% margin) against $24.1M of operating expenses produced $7.1M of operating income, versus a $0.4M operating loss in Q3 2025; net income was $7.0M and diluted EPS $0.17.
-
Cash and Investments Reach $104.3M
Cash and cash equivalents of $55.5M plus $48.8M of short-term investments at September 30, 2026; operations generated $14.7M of net cash in the first nine months, and management says funding covers at least 12 months.
-
Trial Spending Drives Expense Growth
R&D rose to $11.0M from $8.0M and SG&A to $13.1M from $10.3M year over year as the Phase 2 mCRC and mBC trials expand; nine-month R&D was $31.2M versus $19.9M.
Analysis · DCTH · Industrial Applications And Services
The headline numbers were already out this morning via 8-K and press release, but the 10-Q is where the quality of the quarter shows. Gross margin came in at roughly 89% ($31.2M gross profit on $35.1M revenue), and operating income of $7.1M flipped from a $0.4M operating loss a year ago — the company is now profitable on an operating basis, not just on interest income. Cash plus short-term investments totaled $104.3M at September 30, and operations generated $14.7M of cash in the first nine months, so there is no financing overhang. The offset is cost: R&D rose to $11.0M from $8.0M and SG&A to $13.1M from $10.3M as the mCRC and mBC Phase 2 trials ramp, which is why the expense line matters as much as the revenue line going forward. Two customers made up about 31.3% of nine-month revenue, a concentration risk worth noting as receivables build.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DCTH was trading at $18.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $518.1M. The 52-week trading range was $8.12 to $17.42. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.